Personalis (PSNL) Q3 2024 earnings summary

Executive summary

• Achieved Q3 2024 revenue of $25.7 million, up 41% year-over-year, driven by 96% biopharma revenue growth and strong VA MVP demand.

• Raised full-year 2024 revenue guidance due to accelerating growth and strong biopharma performance.

• Delivered 945 clinical/molecular tests in Q3, a 68% sequential increase, with high physician retention and growing NeXT Personal adoption.

• Cash balance of $143.7 million at Q3 end extends runway into the first half of 2027.

• Raised $62.2 million in net financing from Tempus and $27.2 million from ATM stock sales.

Financial highlights

• Q3 2024 revenue: $25.7 million, up from $18.2 million year-over-year.

• Gross margin improved to 34% in Q3 from 19.1% a year ago, driven by favorable mix and operating leverage.

• Net loss for Q3 was $39.1 million, including a $26 million non-cash warrant expense.

• Operating expenses decreased to $23.1 million from $34.3 million year-over-year.

• Cash, cash equivalents, and short-term investments: $143.7 million as of September 30, 2024.

Outlook and guidance

• Full-year 2024 revenue guidance raised to $83–$84 million (previously $79–$81 million).

• Q4 2024 revenue expected at $15–$16 million, with no population sequencing revenue due to VA MVP task order completion.

• Net loss for 2024 projected at ~$85 million, including ~$18 million in non-cash warrant expenses.

• Full-year cash usage expected to be $53–$55 million, down from prior guidance of $60 million.

• Cash runway expected into the first half of 2027.